Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | Director | December 29, 2017 | January 03, 2018 |
| EMISPHERE TECHNOLOGIES INCEMIS · Entity 174671 | Director | May 18, 2017 | May 24, 2017 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date December 29, 2017 · Filed January 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 224,282 |
Ending reported balance
After 2017-12-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-12-29 · Grant · Acquired 17,258 · Balance 230,303 F1: 17,258 shares vest on 12/29/2018. Row 2 · 2017-12-30 · Tax withholding · Disposed 6,021 · Balance 224,282 F2: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. |
Filing footnotes · ownership attribution and instrument terms
F1: 17,258 shares vest on 12/29/2018.
F2: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants.
EMISPHERE TECHNOLOGIES INC
Report date May 18, 2017 · Filed May 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.47 · Expires 2027-05-18 | Direct | 40,000 |
Reported balance
After 2017-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-18 · Grant · Acquired 40,000 · Balance 40,000 F1: One-third of the options subject to this grant shall vest on each of the first three anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the options subject to this grant shall vest on each of the first three anniversaries of the grant date.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 90,316 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 90,316 · Balance 90,316 F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 21:17 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 90,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075863 · tm2618145-5_4seq1.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,316 Underlying: Common Stock · 90,316 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 67,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-060251 · tm2518181-3_4seq1.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,546 Underlying: Common Stock · 67,546 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 49,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-071372 · tm2417165-3_4seq1.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,303 Underlying: Common Stock · 49,303 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:54 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031111 · tm248017-7_4seq1.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:21 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 51,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-069506 · tm2318216-3_4seq1.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,955 Underlying: Common Stock · 51,955 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 51,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071053 · tm2218366-4_4seq1.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,204 Underlying: Common Stock · 51,204 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 00:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 7,813 | $6.80 | $53,128.40 |
DisclosureSEC source: 0001104659-22-067761 · tm2217576d3_4seq1.xml · nonDerivative · entry 2 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,632 Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 00:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 2,187 | $6.79 | $14,849.73 |
DisclosureSEC source: 0001104659-22-067761 · tm2217576d3_4seq1.xml · nonDerivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,819 Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 20:21 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $26.33 | $0.00 |
DisclosureSEC source: 0001104659-21-088253 · tm2121236-5_4seq1.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-06-29 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 29, 2022. Read SEC document |
| June 08, 2020 Filed Jun 11, 2020 00:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $32.17 | $0.00 |
DisclosureSEC source: 0001104659-20-072139 · tm2022303d3_4.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 8, 2021. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 21:16 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $19.93 | $0.00 |
DisclosureSEC source: 0001144204-19-030597 · tv523382_4.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-09 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 12,500 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service, unless the Reporting Person is terminated for cause, in which case the options shall terminate immediately. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 21:39 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $14.45 | $0.00 |
DisclosureSEC source: 0001250853-18-000103 · primary_doc.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-07-16 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service, unless the Reporting Person is terminated for cause, in which case the options shall terminate immediately. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 20:29 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $16.20 | $0.00 |
DisclosureSEC source: 0001250853-18-000043 · primary_doc.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-14 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 12,500 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service unless the Reporting Person is terminated for cause, in which case the options are terminated. Read SEC document |
| December 30, 2017 Filed Jan 3, 2018 22:02 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 6,021 | $4.14 | $24,926.94 |
DisclosureSEC source: 0001209191-18-001023 · doc4.xml · nonDerivative · entry 2 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,282 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:02 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 17,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001023 · doc4.xml · nonDerivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,303 F1 · shares: 17,258 shares vest on 12/29/2018. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 21:34 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001209191-17-065008 · doc4.xml · derivative · entry 3 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2017-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 6,667 shares vested on each of 12/12/08 and 12/12/09; 6,666 shares vested on 12/12/10. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 21:34 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 12,325 | $4.43 | $54,599.75 |
DisclosureSEC source: 0001209191-17-065008 · doc4.xml · nonDerivative · entry 2 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,045 F1 · shares: Represents shares withheld to pay exercise price. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 21:34 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionCommon Stock | 20,000 | $2.73 | $54,600.00 |
DisclosureSEC source: 0001209191-17-065008 · doc4.xml · nonDerivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:28 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-17-039824 · doc4.xml · derivative · entry 3 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 5,000 shares vested and became exercisable on each of 6/18/08, 6/18/09 and 6/18/10. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:28 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 13,300 | $5.47 | $72,751.00 |
DisclosureSEC source: 0001209191-17-039824 · doc4.xml · nonDerivative · entry 2 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,370 F1 · shares: Represents shares withheld to pay exercise price. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:28 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionCommon Stock | 15,000 | $4.85 | $72,750.00 |
DisclosureSEC source: 0001209191-17-039824 · doc4.xml · nonDerivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 24, 2017 16:00 UTC | EMISPHERE TECHNOLOGIES INC EMIS · Entity 174671 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0000899243-17-014232 · doc4.xml · derivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: One-third of the options subject to this grant shall vest on each of the first three anniversaries of the grant date. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:35 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 9,331 | $5.35 | $49,920.85 |
DisclosureSEC source: 0001209191-17-000952 · doc4.xml · nonDerivative · entry 2 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,670 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 21:35 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 17,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-000952 · doc4.xml · nonDerivative · entry 1 WEISER MICHAEL · CIK 0001221449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,001 F1 · shares: 17,204 shares shall vest on 12/30/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.